WallStreetZenWallStreetZen

NASDAQ: XLO
Xilio Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

XLO earnings and revenue history

Current Revenue
$0.0
Current Earnings
-$76.4M
Current Profit Margin
0%

XLO Return on Equity

Current Company
-126.6%
Current Industry
-63.5%
Current Market
188%
XLO's Return on Equity (-126.6%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when XLO announces earnings.

XLO Return on Assets

Current Company
-89.2%
Current Industry
2.9%
XLO is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

XLO Return on Capital Employed

Current Company
-169.9%
Current Industry
19.5%
XLO has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

XLO vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
XLO$0.00-$74.50M-$76.40MN/AN/A
AADI$24.35M-$64.90M-$65.77M+3.85%N/A
NXTC$0.00-$58.47M-$62.72M-100.00%N/A
BOLT$7.88M-$64.39M-$69.20M+146.02%N/A
CTCX$0.00-$14.47M-$16.12MN/AN/A
View Top Biotech Stocks

XLO earnings dates

Next earnings date
May 8, 2024

Xilio Therapeutics Earnings & Revenue FAQ

What were XLO's earnings last quarter?

On Invalid Date, Xilio Therapeutics (NASDAQ: XLO) reported Q4 2023 earnings per share (EPS) of -$0.64, up 21.95% year over year. Total Xilio Therapeutics earnings for the quarter were -$17.66 million. In the same quarter last year, Xilio Therapeutics's earnings per share (EPS) was -$0.82.

If you're new to stock investing, here's how to buy Xilio Therapeutics stock.

What was XLO's earnings growth in the past year?

As of Q2 2024, Xilio Therapeutics's earnings has grown year over year. Xilio Therapeutics's earnings in the past year totalled -$76.40 million.

What is XLO's earnings date?

Xilio Therapeutics's earnings date is Invalid Date. Add XLO to your watchlist to be reminded of XLO's next earnings announcement.

What was XLO's revenue last quarter?

On Invalid Date, Xilio Therapeutics (NASDAQ: XLO) reported Q4 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Xilio Therapeutics's revenue was $0.00.

What was XLO's revenue growth in the past year?

As of Q2 2024, Xilio Therapeutics's revenue has grown null year over year. Xilio Therapeutics's revenue in the past year totalled $0.00.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.